Inhibitory effect of peptide vilon on the development of induced rat urinary bladder tumors in rats.
Pliss. G B GB; Mel'nikov. A S AS; Malinin. V V VV; Khavinson. V K VK
Key Findings
- Vilon reduced overall bladder tumor incidence from 75.5% to 56% in rats.
- The peptide halved the number of preneoplastic and early neoplastic changes in bladder tissue.
- The study used a well‑known bladder carcinogen (N‑butyl‑N-(4‑hydroxybutyl)nitrosamine) to induce tumors.
Practical Outcomes
- The results suggest vilon might have protective effects against bladder cancer in animal models, but there is no human data, dosing information, or safety profile for people. For biohackers, the finding is interesting but not ready to be turned into a supplement or protocol without further research.
Summary
In a rat study, a tiny protein called vilon (made of lysine and glutamic acid) lowered the chance of bladder tumors caused by a specific chemical. Treated rats got tumors at a rate of 56% versus 75.5% in untreated rats, and early cancer‑related changes in the bladder lining were cut roughly in half.
Abstract
The effect of peptide vilon (Lys-Glu) on urinary bladder carcinogenesis in rats was studied. Urinary bladder tumors were induced with a selective carcinogen N-butyl-N-(4-hydroxybutyl)nitrosamine. The tumors developed in 56% vilon-treated animals and in 75.5% controls. Vilon 2-fold decreased the incidence of preneoplastic and early neoplastic changes in urinary bladder mucosa and significantly inhibited carcinogenesis.
Study Information
pubmed
2001
10.1023/a:1012354603132